P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: Relationship to pathology and potential target for treatment

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 5, 2012, Pages 1026-1037

  Young, Christopher N J ^a   Brutkowski, Wojciech ^a   Lien, Chun Fu ^a   Arkle, Stephen ^a   Lochmüller, Hanns ^b   Zabłocki, Krzysztof ^c   Górecki, Dariusz C ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Ca2+ influx; Duchenne muscular dystrophy; ERK signalling; mdx; P2X7; Purinoceptor

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; GAP JUNCTION PROTEIN; ISOPROTEIN; IVERMECTIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE PROTEIN; PANX1 PROTEIN, MOUSE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR;

ANIMAL; ANIMAL MUSCULAR DYSTROPHY; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SKELETAL MUSCLE; UPREGULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CALCIUM; CELL LINE; CONNEXINS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IVERMECTIN; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; UP-REGULATION;

MUS;

EID: 84860327768     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01397.x     Document Type: Article

References (59)

1. Dalkilic I, Kunkel LM. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev. 2003; 13: 231-8.
2. Millay DP, Goonasekera SA, Sargent MA, et al. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci U S A. 2009; 106: 19023-8.
3. Yeung D, Zablocki K, Lien CF, et al. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. FASEB J. 2006; 20: 610-20.
4. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006; 442: 527-32.
5. Buvinic S, Almarza G, Bustamante M, et al. ATP released by electrical stimuli elicits calcium transients and gene expression in skeletal muscle. J Biol Chem. 2009; 284: 34490-505.
6. Yokota T, Lu QL, Morgan JE, et al. Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci. 2006; 119: 2679-87.
7. Coutinho-Silva R, Ojcius DM, Gorecki DC, et al. Multiple P2X and P2Y receptor subtypes in mouse J774, spleen and peritoneal macrophages. Biochem Pharmacol. 2005; 69: 641-55.
8. Rosenblatt JD, Lunt AI, Parry DJ, et al. Culturing muscle cells from single living muscle fibre explants. J Biol Chem. 2009; 284: 25813-22.
9. Rosenblatt JD, Lunt AI, Parry DJ, et al. In vitro cell. Dev. Biol.-Animal 2005; 31: 773-779.
10. Nicke A, Kuan YH, Masin M, et al. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem. 2009; 284: 25813-22.
11. Beresewicz M, Majewska M, Makarewicz D, et al. Changes in the expression of insulin-like growth factor 1 variants in the postnatal brain development and in neonatal hypoxia-ischaemia. Int J Dev Neurosci. 2010; 28: 91-7.
12. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image. J. Biophoton Int. 2004; 11: 36-42.
13. Donnelly-Roberts DL, Namovic MT, Han P, et al. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol. 2009; 157: 1203-14.
14. Cheewatrakoolpong B, Gilchrest H, Anthes JC, et al. Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun. 2005; 332: 17-27.
15. Feng YH, Li X, Wang L, et al. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006; 281: 17228-37.
16. Sim JA, Young MT, Sung HY, et al. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci. 2004; 24: 6307-14.
17. Masin M, Young C, Lim K, et al. Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J Pharmacol. 2011; in press: doi:10.1111/j.1476-5381.2011.01624.x.
18. Boumechache M, Masin M, Edwardson JM, et al. Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. J Biol Chem. 2009; 284: 13446-54.
19. Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004; 123: 281-93.
20. Budagian V, Bulanova E, Brovko L, et al. Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J Biol Chem. 2003; 278: 1549-60.
21. 2+ influx. Biochem J. 2003; 374: 51-61.
22. Hong S, Schwarz N, Brass A, et al. Differential regulation of P2X7 receptor activation by extracellular nicotinamide adenine dinucleotide and ecto-ADP-ribosyltransferases in murine macrophages and T cells. J Immunol. 2009; 183: 578-92.
23. Schachter J, Motta AP, de Souza Zamorano A, et al. ATP-induced P2X7-associated uptake of large molecules involves distinct mechanisms for cations and anions in macrophages. J Cell Sci. 2008; 121: 3261-70.
24. Vessey DA, Li L, Kelley M. Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischaemic pre- and postconditioning. J Cardiovasc Pharmacol Ther. 2010; 15: 190-5.
25. Yeung D, Kharidia R, Brown SC, et al. Enhanced expression of the P2X4 receptor in Duchenne muscular dystrophy correlates with macrophage invasion. Neurobiol Dis. 2004; 15: 212-20.
26. Kolb HA, Wakelam MJ. Transmitter-like action of ATP on patched membranes of cultured myoblasts and myotubes. Nature. 1983; 303: 621-3.
27. Vizi ES, Nitahara K, Sato K, et al. Stimulation-dependent release, breakdown, and action of endogenous ATP in mouse hemidiaphragm preparation: the possible role of ATP in neuromuscular transmission. J Auton Nerv Syst. 2000; 81: 278-84.
28. Lu Z, Smith DO. Adenosine 5′-triphosphate increases acetylcholine channel opening frequency in rat skeletal muscle. J Physiol. 1991; 436: 45-56.
29. Martinello T, Baldoin MC, Morbiato L, et al. Extracellular ATP signaling during differentiation of C2C12 skeletal muscle cells: role in proliferation. Mol Cell Biochem. 2011; 351: 183-96.
30. Deli T, Toth BI, Czifra G, Szappanos H, et al. Differences in purinergic and voltage-dependent signalling during protein kinase Calpha overexpression- and culturing-induced differentiation of C2C12 myoblasts. J Muscle Res Cell Motil. 2006; 27: 617-30.
31. Araya R, Riquelme MA, Brandan E, et al. The formation of skeletal muscle myotubes requires functional membrane receptors activated by extracellular ATP. Brain Res Brain Res Rev. 2004; 47: 174-88.
32. Ryten M, Dunn PM, Neary JT, et al. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J Cell Biol. 2002; 158: 345-55.
33. Ryten M, Koshi R, Knight GE, et al. Abnormalities in neuromuscular junction structure and skeletal muscle function in mice lacking the P2X2 nucleotide receptor. Neuroscience. 2007; 148: 700-11.
34. Choi RC, Man ML, Ling KK, et al. Expression of the P2Y1 nucleotide receptor in chick muscle: its functional role in the regulation of acetylcholinesterase and acetylcholine receptor. J Neurosci. 2001; 21: 9224-34.
35. Jiang LH, Rassendren F, Mackenzie A, et al. N-methyl-D-glucamine and propidium dyes utilize different permeation pathways at rat P2X(7) receptors. Am J Physiol Cell Physiol. 2005; 289: C1295-302.
36. Rawat R, Cohen TV, Ampong B, et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol. 2010; 176: 2891-900.
37. Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2010; 24: 337-45.
38. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007; 28: 465-72.
39. Coolican SA, Samuel DS, Ewton DZ, et al. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem. 1997; 272: 6653-62.
40. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science. 1997; 278: 1288-91.
41. Wu Z, Woodring PJ, Bhakta KS, et al. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol. 2000; 20: 3951-64.
42. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science. 1999; 286: 1738-41.
43. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol. 2009; 71: 333-59.
44. Di Virgilio F, Ferrari D, Adinolfi E. P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal. 2009; 5: 251-6.
45. Ponnusamy M, Ma L, Gong R, et al. P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol. 2011; 300: F62-70.
46. Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002; 11: 263-72.
47. Serrano AL, Baeza-Raja B, Perdiguero E, et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008; 7: 33-44.
48. Ferrari D, Munerati M, Melchiorri L, et al. Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am J Physiol. 1994; 267: C886-92.
49. Onopiuk M, Brutkowski W, Wierzbicka K, et al. Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts. Biochem Biophys Res Commun. 2009; 386: 463-6.
50. Merrick D, Stadler LK, Larner D, et al. Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation. Dis Model Mech. 2009; 2: 374-88.
51. Yan Z, Li S, Liang Z, et al. The P2X7 receptor channel pore dilates under physiological ion conditions. J Gen Physiol. 2008; 132: 563-73.
52. Vandebrouck A, Ducret T, Basset O, et al. Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J. 2006; 20: 136-8.
53. Vandebrouck C, Martin D, Colson-Van Schoor M, et al. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol. 2002; 158: 1089-96.
54. Kumar A, Khandelwal N, Malya R, et al. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 2004; 18: 102-13.
55. Iwata Y, Katanosaka Y, Arai Y, et al. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J Cell Biol. 2003; 161: 957-67.
56. Friedrich O, Both M, Gillis JM, et al. Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. J Physiol. 2004; 555: 251-65.
57. Matsumura CY, Pertille A, Albuquerque TC, et al. Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability. Muscle Nerve. 2009; 39: 167-76.
58. Taniguti AP, Pertille A, Matsumura CY, et al. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker. Muscle Nerve. 2011; 43: 82-7.
59. Iwata Y, Katanosaka Y, Hisamitsu T, Wakabayashi S. Enhanced Na+/H +exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors. Am J Pathol. 2007; 171: 1576-87.